Survival and toxicity outcomes of somatostatin analogues vs. other systemic therapies as first-line palliative treatment for patients with extrapulmonary G2 well-differentiated neuroendocrine tumours with a Ki-67 index between 10% and 20%

#4535

Introduction: In patients (pts) with an advanced well-differentiated (WD-NET) with a Ki-67>10% and ≤20% (“G2 high”), chemotherapy (ChT) or targeted therapies are the preferred first-line palliative options. Somatostatin analogues (SSAs) may offer an alternative, yet randomised evidence is lacking.

Aim(s): Retrospective cohort of pts with an advanced “G2 high” WD-NET of extrapulmonary origin (diagnosis; 01/01/2014 – 31/12/2023) who received first-line SSAs or other systemic therapies (non-SSAs) at The Christie NHS Foundation Trust.

Materials and methods: Compare progression-free survival (PFS) and Common Terminology Criteria for Adverse Events v5.0 toxicity rates between SSAs and non-SSAs.

Conference:

Presenting Author:

Authors: Dawoodji A, Nuttall C, Eyong M, Farrell K, Barratt N,

Keywords: somatostatin analogue, SSA, non-SSA, Grade 2 well-differentiated neuroendocrine tumour, WD-NET,